Shire’s Experimental Gene Therapy Delivery Strategies Show Potential for Hemophilia A and B – Hemophilia News Today
Hemophilia News Today |
Shire's Experimental Gene Therapy Delivery Strategies Show Potential for Hemophilia A and B
Hemophilia News Today Shire is developing a potential new strategy to improve the effectiveness of genetic delivery of clotting factor VIII (FVIII) for the treatment of patients with hemophilia A, and clotting factor IX (FIX) for patients with hemophilia B. The most recent … |
